Precigen Inc (PGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -0.409x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.81 Million) by net assets ($43.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PGEN company net worth for the company's overall valuation and market capitalisation.
Precigen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency. Explore Precigen Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P/F Bakkafrost
F:6BF
|
0.040x |
|
Enerflex Ltd.
NYSE:EFXT
|
0.028x |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
0.024x |
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
-0.536x |
|
Liberty Live Holdings, Inc. Series A Liberty Live Group Common Stock
NASDAQ:LLYVA
|
-0.523x |
|
Elmos Semiconductor SE
F:ELG
|
0.009x |
|
Sociedad Punta del Cobre S.A
SN:PUCOBRE
|
0.013x |
|
Boyd Group Services Inc.
NYSE:BGSI
|
0.044x |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2025. View Precigen Inc (PGEN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.91 Million | $-87.83 Million | -4.200x | -137.28% |
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more